HESTER BIOSCIENCES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,633 INR | +0.69% |
|
+2.67% | +12.00% |
| Feb. 29 | Hester Biosciences Names COO | MT |
| Feb. 29 | Hester Biosciences Limited Announces Executive Changes | CI |
| Sales 2022 | 2.47B 29.6M | Sales 2023 | 2.78B 33.38M | Capitalization | 12.93B 155M |
|---|---|---|---|---|---|
| Net income 2022 | 393M 4.72M | Net income 2023 | 266M 3.19M | EV / Sales 2022 | 10.2 x |
| Net Debt 2022 | 2.03B 24.36M | Net Debt 2023 | 2.59B 31.12M | EV / Sales 2023 | 5.58 x |
| P/E ratio 2022 |
58.7
x | P/E ratio 2023 |
48.6
x | Employees | 693 |
| Yield 2022 |
0.37% | Yield 2023 |
0.53% | Free-Float | 34.24% |
More Fundamentals
* Assessed data
More news
Latest transcript on Hester Biosciences Limited
More recommendations
| 1 day | +0.69% | ||
| 1 week | +2.67% | ||
| Current month | +17.10% | ||
| 1 month | +22.94% | ||
| 3 months | +5.81% | ||
| 6 months | -2.63% | ||
| Current year | +12.00% |
1 week
1 549.80
1 640.00
1 month
1 331.001 679.00
Current year
1 292.851 679.00
1 year
1 292.851 939.95
3 years
1 292.853 134.00
5 years
864.003 134.00
10 years
363.003 134.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 61 | 87-04-28 | |
Nikhil Jhanwar
DFI | Director of Finance/CFO | - | 21-06-08 |
Vinod Mali
CMP | Compliance Officer | - | 18-05-13 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 60 | - | |
| Chairman | 81 | 05-04-20 | |
| Founder | 61 | 87-04-28 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 1,633 | +0.69% | 5,591 |
| 24-04-18 | 1,622 | +0.54% | 10,698 |
| 24-04-16 | 1,613 | +1.72% | 4,167 |
| 24-04-15 | 1,586 | -0.77% | 3,295 |
| 24-04-12 | 1,598 | +0.48% | 6,585 |
Delayed Quote NSE India S.E., April 19, 2024 at 07:43 am EDT
More quotes
Hester Biosciences Limited is an India-based animal healthcare company. The Company is engaged in providing vaccines, health products and diagnostic laboratory services. The Company operates through four segments: Poultry Healthcare, Animal Healthcare, Petcare, and Others. The Animal Healthcare vaccines include Goat Pox Vaccine, Live Brucella, PPR Vaccine - Nigerian 75/1, and PPR Vaccine - Sungri/96. Its Poultry Healthcare products include Gumboro I, Gumboro I +, Inactivated Chick ND, Inactivated Coryza, Inactivated Coryza+, Inactivated EDS, Inactivated FC3, Inactivated FC4, Inactivated IB, Inactivated IB+, Inactivated IB-H52, Inactivated IBD, Inactivated IBD ND, Inactivated IBD ND EDS, Inactivated ND IB, Inactivated Pullet ND, Live B1, Live B1 M48, Live FP, Live H120, Live Las, Live Las Mas, Live M48, Live R2B, Live S-One, MD-Bivalent HVT+SB1, MD-HVT (FD), and Thermostable ND. Its Petcare products include Cefshot Tazo Injection, Hestacef CV, Hestacef DS, Hestaflam Tablet and Hestaliv.
Sector
Pharmaceuticals
Calendar
2024-05-14
- Q4 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -13.09% | 6.69B | |
| +15.00% | 3.35B | |
| +4.59% | 3.33B | |
| +2.70% | 1.46B | |
| -18.20% | 1.33B | |
| -6.15% | 1.19B | |
| -29.51% | 1.19B | |
| -18.20% | 1.08B | |
| -2.50% | 1.01B |
- Stock Market
- Equities
- HESTERBIO Stock
- HESTERBIO Stock
